A regulatory setback for Moderna’s next-generation flu vaccine underscores mounting scrutiny of late-stage trial design in the U.S., even as the company pivots to international manufacturing ...
Asianet Newsable on MSN
Why did Moderna stock tumble nearly 10% after hours today?
The FDA’s CBER issued a refusal-to-file letter for Moderna’s flu vaccine mRNA-1010.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results